In Q4 2024, Deerfield Management held 68 positions worth $4.1B. They initiated 9 new positions and exited 542. Their largest holding was NUVL ($1.4B). Portfolio value shrank -21.8% versus the prior quarter.
Frequently asked questions
What stocks did Deerfield Management own in Q4 2024?
Deerfield Management held 68 biotech stocks in their 13F portfolio in Q4 2024. Their top positions include NUVL, VTRS, OSCR, RVMD, WAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deerfield Management's portfolio worth in Q4 2024?
Deerfield Management's tracked biotech portfolio was worth $4.1B across 68 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
What did Deerfield Management buy in Q4 2024?
Deerfield Management initiated 9 new positions in Q4 2024, including LEGN, KYMR, SEPN, SYRE, NGNE and 4 more. They also increased 25 existing positions.
What did Deerfield Management sell in Q4 2024?
Deerfield Management fully exited 542 positions in Q4 2024, including RILYZ, WRB-PH, CGBD, MRNA, MET-PF and 537 more. They also trimmed 16 existing positions.
Is Deerfield Management a biotech fund?
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Want AI analysis, insider signals, and catalyst overlays for Deerfield Management?
View latest Deerfield Management portfolio →